Scholarlink

Purpose of Review <p>To examine the development, performance, and potential integration of three commercially available gene expression profiling (GEP) assays for primary melanoma into clinical practice through a comparative and evidence-based lens.</p> Recent Findings <p>Recent prospective data has shown the ability for GEP assays to provide additional objective data in stratifying risk of sentinel node positivity for primary melanoma.</p> Summary <p>GEP assays have emerged for patients with melanoma to better define individual metastatic risk based on tumor-intrinsic biology and refine decisions around SLNB, surveillance, and adjuvant therapy. While prospective evidence is currently insufficient to show the associated prognostic value of these tests improves clinical outcomes in all patients with melanoma over clinicopathologic variables alone, these assays may serve as a useful and objective adjunct in clinical decision-making promoting personalized care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Gene Expression Profiling for Melanoma Risk Stratification: Where do we Stand?

  • 期刊论文

  • 发表日期：

    2026年3月11日

查看全文
  • Matthew C. Perez,
  • Rogerio I. Neves,
  • Jane L. Messina,
  • Tina J. Hieken,
  • Michael E. Egger,
  • Vernon K. Sondak

摘要

Purpose of Review

To examine the development, performance, and potential integration of three commercially available gene expression profiling (GEP) assays for primary melanoma into clinical practice through a comparative and evidence-based lens.

Recent Findings

Recent prospective data has shown the ability for GEP assays to provide additional objective data in stratifying risk of sentinel node positivity for primary melanoma.

Summary

GEP assays have emerged for patients with melanoma to better define individual metastatic risk based on tumor-intrinsic biology and refine decisions around SLNB, surveillance, and adjuvant therapy. While prospective evidence is currently insufficient to show the associated prognostic value of these tests improves clinical outcomes in all patients with melanoma over clinicopathologic variables alone, these assays may serve as a useful and objective adjunct in clinical decision-making promoting personalized care.